SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Slideset
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Video
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Slideset
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Video
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Slideset
VideoTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Video
SlidesetTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Slideset
JCJessica CusatoBSc, MSc, PhDVideoViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Video
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Slideset
JCJessica CusatoBSc, MSc, PhDVideoViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Pharmacology of HDV - Jessica CusatoView Video
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Pharmacology of HDV - Jessica CusatoView Slideset
KWCKeith W. CrawfordRPh, PhDVideo26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025NIH Initiatives and Research Promoting Antiviral Pharmacology - Keith W. CrawfordView Video
